Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 28;18(9):702-710.
doi: 10.11909/j.issn.1671-5411.2021.09.005.

In-hospital outcomes of transapical versus surgical aortic valve replacement: from the U.S. national inpatient sample

Affiliations

In-hospital outcomes of transapical versus surgical aortic valve replacement: from the U.S. national inpatient sample

Ashraf Abugroun et al. J Geriatr Cardiol. .

Abstract

Objective: To compare the outcomes of transapical transcatheter aortic valve replacement (TA-TAVR) and surgical aortic valve replacement (SAVR) using a large US population sample.

Methods: The U.S. National Inpatient Sample was queried for all patients who underwent TA-TAVR or SAVR during the years 2016-2017. The primary outcome was all-cause in-hospital mortality. Secondary outcomes were in-hospital stroke, pericardiocentesis, pacemaker insertion, mechanical ventilation, vascular complications, major bleeding, acute kidney injury, length of stay, and cost of hospitalization. Outcomes were modeled using multi-variable logistic regression for binary outcomes and generalized linear models for continuous outcomes.

Results: A total of 1560 TA-TAVR and 44,280 SAVR patients were included. Patients who underwent TA-TAVR were older and frailer. Compared to SAVR, TA-TAVR correlated with a higher mortality (4.5% vs. 2.7%, effect size (SMD) = 0.1) and higher periprocedural complications. Following multivariable analysis, both TA-TAVR and SAVR had a similar adjusted risk for in-hospital mortality. TA-TAVR correlated with lower odds of bleeding with (adjusted OR (aOR) = 0.26; 95% CI: 0.18-0.38;P < 0.001), and a shorter length of stay (adjusted mean ratio (aMR) = 0.77; 95% CI: 0.69-0.84; P < 0.001), but higher cost (aMR = 1.18; 95% CI: 1.10-1.28; P < 0.001). No significant differences in other study outcomes. In subgroup analysis, TA-TAVR in patients with chronic lung disease had higher odds for mortality (aOR = 3.11; 95%CI: 1.37-7.08; P = 0.007).

Conclusion: The risk-adjusted analysis showed that TA-TAVR has no advantage over SAVR except for patients with chronic lung disease where TA-TAVR has higher mortality.

PubMed Disclaimer

Conflict of interest statement

None

Figures

Figure 1
Figure 1
Algorithm for selection of study population.
Figure 2
Figure 2
Adjusted complication rates among TA-TAVR vs. SAVR.

References

    1. Madigan M, Atoui R Non-transfemoral access sites for transcatheter aortic valve replacement. J Thorac Dis. 2018;10:4505–4515. doi: 10.21037/jtd.2018.06.150. - DOI - PMC - PubMed
    1. Nielsen HHM, Klaaborg KE, Nissen H, et al A prospective, randomised trial of transapical transcatheter aortic valve implantation vs. surgical aortic valve replacement in operable elderly patients with aortic stenosis: the STACCATO trial . EuroIntervention. 2012;8:383–389. doi: 10.4244/EIJV8I3A58. - DOI - PubMed
    1. Abugroun A, Daoud H, Abdel-Rahman ME, et al National trends of outcomes in transcatheter aortic valve replacement (TAVR) through transapical versus endovascular approach: From the National Inpatient Sample (NIS) Cardiovasc Revasc Med. 2020;21:964–970. doi: 10.1016/j.carrev.2020.05.010. - DOI - PubMed
    1. HCUP-US Home Page. https://www.hcup-us.ahrq.gov/ (accessed on January 15, 2021).

    1. Gilbert T, Neuburger J, Kraindler J, et al Development and validation of a Hospital Frailty Risk Score focusing on older people in acute care settings using electronic hospital records: an observational study. Lancet. 2018;391:1775–1782. doi: 10.1016/S0140-6736(18)30668-8. - DOI - PMC - PubMed